Small Ne­bras­ka start­up hopes to chal­lenge Pfiz­er, Mer­ck in pneu­mo­coc­cal vac­cine race

A new biotech out of Lin­coln, NE, launched Mon­day aim­ing to tack­le what it says is an un­ad­dressed need in the pneu­mo­coc­cal vac­cine space.

Ae­o­lian Biotech de­buted with a promise to fill the gaps left by cur­rent­ly ap­proved pneu­mo­coc­cal vac­cines us­ing its own shot. The com­pa­ny aims to ac­com­plish this with its sole can­di­date, iPCV22, which was de­vel­oped by for­mer Wyeth/Pfiz­er re­searchers Jack Love and Bruce For­rest, who worked on the Pre­vnar project and are now Ae­o­lian co-founders.

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER